

Iconovo receives approval of additional patent for ICORES® in the EU

Iconovo AB (publ), that develops complete inhalation products for a global market, today announced that the European Patent Office (EPO) has provided a Notice of Allowance regarding an additional patent application for the inhaler platform ICORES. ICORES is currently being used in several of Iconovo's customer projects and this additional patent will bring a longer and improved protection period for customers launching in the future.

This Notice of Allowance from the European Patent Office is further reinforcing the patent protection of Iconovo's inhalation device, ICORES. Iconovo has already been granted several ICORES patents in the U.S., Europe, China, and Japan.

"The notification from the European Patent Office further strengthens our international intellectual property and increases the value of our product portfolio. This complementary patent can provide our customers with additional protection and market exclusivity when launching ICORES products in the European market," said Dr. Orest Lastow, CTO of Iconovo.

About ICORES®

ICORES is a dry powder inhaler similar in handling to AstraZeneca's best-selling Turbuhaler®. ICORES has an exact dose counter that allows the patient to know exactly how many doses are left. Another advantage is that the inhaler also gives the patient a visual confirmation when a dose has been inhaled correctly, thereby minimising the risk of incorrect handling. ICORES is the only reservoir inhaler that can be filled with up to three different drug substances, a strong competitive advantage as triple products are expected to be the next big area in inhalation therapy.

Contacts

Johan Wäborg, CEO

+46 707 78 51 71

johan.waborg@iconovo.se

About Iconovo

Iconovo (Nasdaq First North Growth Market: ICO) develops new inhaled medicinal products in collaboration with international pharmaceutical companies. The company provides several types of patent-protected inhalers that can generate significant commercial opportunities in the development of novel pharmaceuticals and vaccines and at patent expirations for established pharmaceuticals. The most advanced project is a generic version of the asthma and COPD product Symbicort® which is expected to reach the market in 2024. Iconovo plans to market this product in the Nordic region through its subsidiary Iconovo Pharma, while the company's partner Amneal Pharmaceuticals has the rights in other parts of Europe and the United States. Certified Adviser is Erik Penser Bank AB, Box 7405, SE-103 91 Stockholm (+46 8 463 80 00, certifiedadviser@penser.se).

Attachments

[Iconovo receives approval of additional patent for ICORES® in the EU](#)

PRESS RELEASE
13 June 2022 14:00:00 CEST

